Answers are grounded in this paper and cite their sources.
Randomized double-blind trial reports individual patient responses over time in EGFR-mutated stage IV lung adenocarcinoma, suggesting nicotinamide activity with EGFR tyrosine kinase inhibitors.
Figure S3. Spider plot showing individual patient responses over time in both the nicotinamide and placebo groups.
No takes yet. Share an insight, caveat, or question.
Oh et al. (2024) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: